Welcome to the e-CCO Library!

DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Liu, X.(1,2)*;Tang, H.(3);Zhou, Q.(1);Zeng, Y.(1,4);Lu, B.(1);Chen, M.(5);Xu, Y.(5);Wang, M.(5);Li, Y.(1);Tan, B.(1);Qian, J.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP47: Identification and characterization of T-cell receptor sequences associated with Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Pesesky, M.(1);Carty, C.L.(1);Singh, N.(2);Le Bourhis, L.(3);Rosati, E.(4);Bokemeyer, B.(5);Schreiber, S.(4);Görg, S.(6);Gittelman, R.M.(1);Dines, J.N.(2);Kaplan, I.M.(7);Zahid, H.J.(8);Baldo, L.(2);Snyder, T.M.(1);Robins, H.S.(1);Franke, A.(4);Allez, M.(3);
Created: Friday, 11 February 2022, 3:52 PM
DOP47: Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD Study
Year: 2021
Source: ECCO'21 Virtual
Authors: Bokemeyer, B.(1);Plachta-Danielzik, S.(2);Di Giuseppe, R.(3);Mohl, W.(4);Teich, N.(5);Hoffstadt, M.(6);Schweitzer, A.(7);von der Ohe, M.(8);Gauss, A.(9);Atreya, R.(10);Krause, T.(11);Blumenstein, I.(12);Höchstödter, J.(2);Hartmann , P.(1);Schreiber, S.(13)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Van Assche*1, S. R. Targan2, T. Baker3, C. D. O’Brien3, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4,5, D. Rowbotham6,7, T. Hisamatsu8, S. Danese9, B. E. Sands10, L. Peyrin-Biroulet11

Created: Friday, 22 February 2019, 9:41 AM
DOP48 Gene expression landscape of epithelial monolayer in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Sæterstad1, A.E. Østvik2,3, A.K. Sandvik1,2,3, A. Granlund Van Beelen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. D’Haens*1, S. Danese2, M. Davies3, M. Watanabe4, T. Hibi5

Created: Friday, 22 February 2019, 9:41 AM
DOP48: Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBD
Year: 2022
Source: ECCO'22
Authors: Hanna, J.(1);Beke, F.(2);O'Brien, L.(2);Kapeni, C.(2);Chen, H.C.(2);Carbonaro, V.(2);Kim, A.(3);Kishore, K.(2);Adolph, T.E.(4);Skjoedt, M.O.(5);Skjoedt, K.(6);de la Roche, M.(7);de la Roche, M.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP48: Key Anti-Inflammatory Faecalibacterium prausnitzii is Heterogeneous and Diverse in the East and West and in Health and Crohn's disease. The ENIGMA study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Teh, J.J.(1);Kang, S.(1);Leonard, A.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching , J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP48: Use of biologic therapies with different mechanisms of action (MOA) in the first-line (1L) treatment of Crohn’s Disease (CD) in the U.S.
Year: 2021
Source: ECCO'21 Virtual
Authors: Huang, Z.(1);Ba, Y.(1);Kamble, P.(1);Wang, S.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP49 Quantitative proteomics analysis of macrophages from Crohn’s disease patients and infected with adherent-invasive Escherichia coli
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Douadi1, E. Vazeille1, C. Chambon2, M. Hébraud3, M. Dodel4, B. Pereira4, D. Coban4, A. Buisson4, N. Barnich1

Created: Thursday, 30 January 2020, 10:12 AM
DOP49: Context-dependent roles of High-mobility group box 1 (HMGB1) during intestinal inflammation and carcinogenesis
Year: 2022
Source: ECCO'22
Authors: Zierz, E.(1);Foelsch, K.(1);Pelczar, P.(1);Qi, M.(2);Alawi, M.(2);Clauditz, T.(3);Gagliani, N.(4);Huber, S.(1);Huebener, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP49: Effectiveness and safety of vedolizumab in a matched cohort of elderly and young Inflammatory Bowel Disease patients - LIVE Study-Group
Year: 2021
Source: ECCO'21 Virtual
Authors: Pugliese, D.(1);Privitera, G.(2);Armuzzi, A.(3)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

Created: Friday, 22 February 2019, 9:41 AM
DOP49: Metagenomic Characterisation of The Colonic Mucosa-Associated Microbiota Reveals Novel Microbes and Communities in Health and Crohn's disease. The ENIGMA study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kang, S.(1);Teh, J.J.(1);Zhang, J.(2,3,4);Hu, J.(2,3,4);Hamilton, A.L.(5,6);Wilson-O'Brien, A.(5,6);Trakman, G.L.(5,6);Lin, W.(2,3,4);Ching, J.(2,4);Sung, J.J.Y.(7);Yu, J.(2,4);Ng, S.C.(2,3,8);Kamm, M.A.(5,6)*;Morrison, M.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Olafsson1, R.E. McIntyre1, T. Coorens2, T. Butler2, P. Robinson2, H. Lee-Six2, M. Sanders2, K. Arestang3, C. Dawson3, M. Tripathi4, K. Strongili3, Y. Hooks2, M.R. Stratton2, M. Parkes3, I. Martincorena2, T. Raine3, P.J. Campbell2, C.A. Anderson1

Created: Thursday, 30 January 2020, 10:12 AM
DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Peyrin-Biroulet*1, S. Danese2, E. Louis3, P. D. R. Higgins4, M. Dubinsky5, F. Cataldi6, Q. Zhou6, W-J. Lee6, K. Kligys6, A. P. Lacerda6

Created: Friday, 22 February 2019, 9:41 AM
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiota
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Grellier, N.(1,2,3)*;Suzuki, M.(4);Brot, L.(1);Rodrigues, A.(4);Humbert, L.(1);Escoubeyrou, K.(4);Rainteau, D.(1);Grill, J.P.(1);Lami, R.(4);Seksik, P.(1,3);
Created: Friday, 14 July 2023, 10:43 AM
DOP50: Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates
Year: 2022
Source: ECCO'22
Authors: Wong, J.(1);Lee, D.(2);Mangada, M.(3);Yadav, V.(3);Troast, D.(4);Zhong, C.(4);Hahn, K.(4);Wang, W.(5);Ge, X.(5);Sun, L.(5);Jiang, S.(5);Wang, B.(5);Zhang, J.(5);Yan, L.(5);Nguyen, H.(6);Cui, D.(2);Bursavich, M.G.(4);Lippa, B.(4);Rogers, B.N.(7);Ray, A.S.(8);
Created: Friday, 11 February 2022, 3:52 PM
DOP50: Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Ledder, O.(1);Lujan, R.(1);Orlanski-Meyer, E.(1);Friss, C.(1);Loewenberg Weisband, Y.(2);Greenfeld, S.(3);Kariv, R.(3);Lederman, N.(4);Matz, E.(5);Focht, G.(1);Yanai, H.(6);Ollech, Y.(6);Dotan, I.(6);Turner, D.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Branchi, C. Heldt, B. Siegmund, M. Schumann

Created: Thursday, 30 January 2020, 10:12 AM